JP Morgan Chase’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.26B | Sell |
6,517,600
-515,556
| -7% | -$228M | 0.18% | 123 |
|
|
2026
Q1 | $3.12B | Buy |
7,033,156
+993,675
| +16% | +$463M | 0.2% | 109 |
|
|
2025
Q4 | $2.74B | Sell |
6,039,481
-395,297
| -6% | -$170M | 0.17% | 125 |
|
|
2025
Q3 | $2.52B | Buy |
6,434,778
+565,417
| +10% | +$236M | 0.15% | 141 |
|
|
2025
Q2 | $2.61B | Sell |
5,869,361
-1,886,284
| -24% | -$869M | 0.17% | 124 |
|
|
2025
Q1 | $3.76B | Buy |
7,755,645
+1,442,538
| +23% | +$672M | 0.27% | 82 |
|
|
2024
Q4 | $2.54B | Sell |
6,313,107
-615,480
| -9% | -$285M | 0.19% | 120 |
|
|
2024
Q3 | $3.22B | Buy |
6,928,587
+328,802
| +5% | +$158M | 0.24% | 92 |
|
|
2024
Q2 | $3.09B | Buy |
6,599,785
+581,661
| +10% | +$252M | 0.25% | 85 |
|
|
2024
Q1 | $2.52B | Buy |
6,018,124
+393,859
| +7% | +$167M | 0.21% | 101 |
|
|
2023
Q4 | $2.29B | Sell |
5,624,265
-481,587
| -8% | -$178M | 0.22% | 104 |
|
|
2023
Q3 | $2.12B | Buy |
6,105,852
+150,327
| +3% | +$52.6M | 0.23% | 95 |
|
|
2023
Q2 | $2.1B | Sell |
5,955,525
-405,233
| -6% | -$137M | 0.23% | 101 |
|
|
2023
Q1 | $2B | Buy |
6,360,758
+870,350
| +16% | +$261M | 0.24% | 100 |
|
|
2022
Q4 | $1.59B | Buy |
5,490,408
+630,721
| +13% | +$192M | 0.21% | 113 |
|
|
2022
Q3 | $1.41B | Sell |
4,859,687
-377,855
| -7% | -$109M | 0.2% | 118 |
|
|
2022
Q2 | $1.48B | Buy |
5,237,542
+424,873
| +9% | +$114M | 0.21% | 110 |
|
|
2022
Q1 | $1.26B | Buy |
4,812,669
+348,338
| +8% | +$82.7M | 0.15% | 150 |
|
|
2021
Q4 | $980M | Buy |
4,464,331
+252,599
| +6% | +$49.1M | 0.11% | 201 |
|
|
2021
Q3 | $764M | Sell |
4,211,732
-226,331
| -5% | -$44.2M | 0.09% | 229 |
|
|
2021
Q2 | $895M | Buy |
4,438,063
+1,231,763
| +38% | +$258M | 0.11% | 213 |
|
|
2021
Q1 | $689M | Buy |
3,206,300
+618,276
| +24% | +$136M | 0.09% | 235 |
|
|
2020
Q4 | $612M | Buy |
2,588,024
+348,214
| +16% | +$79.9M | 0.09% | 236 |
|
|
2020
Q3 | $605M | Buy |
2,239,810
+126,724
| +6% | +$35M | 0.1% | 206 |
|
|
2020
Q2 | $613M | Sell |
2,113,086
-81,689
| -4% | -$22.1M | 0.12% | 187 |
|
|
2020
Q1 | $522M | Sell |
2,194,775
-390,614
| -15% | -$89.6M | 0.12% | 177 |
|
|
2019
Q4 | $566M | Sell |
2,585,389
-788,425
| -23% | -$160M | 0.11% | 204 |
|
|
2019
Q3 | $572M | Sell |
3,373,814
-959,889
| -22% | -$170M | 0.11% | 193 |
|
|
2019
Q2 | $774M | Sell |
4,333,703
-2,449,932
| -36% | -$428M | 0.15% | 146 |
|
|
2019
Q1 | $1.25B | Sell |
6,783,635
-403,886
| -6% | -$74.6M | 0.25% | 87 |
|
|
2018
Q4 | $1.19B | Buy |
7,187,521
+70,305
| +1% | +$12.2M | 0.28% | 78 |
|
|
2018
Q3 | $1.37B | Buy |
7,117,216
+355,139
| +5% | +$63.2M | 0.26% | 75 |
|
|
2018
Q2 | $1.15B | Sell |
6,762,077
-1,222,383
| -15% | -$189M | 0.24% | 87 |
|
|
2018
Q1 | $1.3B | Sell |
7,984,460
-1,413,492
| -15% | -$231M | 0.28% | 65 |
|
|
2017
Q4 | $1.41B | Buy |
9,397,952
+75,505
| +0.8% | +$11.2M | 0.3% | 63 |
|
|
2017
Q3 | $1.39B | Buy |
9,322,447
+939,894
| +11% | +$141M | 0.31% | 64 |
|
|
2017
Q2 | $1.08B | Sell |
8,382,553
-978,823
| -10% | -$118M | 0.25% | 84 |
|
|
2017
Q1 | $1.02B | Sell |
9,361,376
-1,235,572
| -12% | -$109M | 0.23% | 89 |
|
|
2016
Q4 | $781M | Sell |
10,596,948
-430,141
| -4% | -$35M | 0.19% | 120 |
|
|
2016
Q3 | $962M | Sell |
11,027,089
-1,146,350
| -9% | -$108M | 0.24% | 93 |
|
|
2016
Q2 | $1.05B | Buy |
12,173,439
+485,112
| +4% | +$41.9M | 0.26% | 86 |
|
|
2016
Q1 | $929M | Sell |
11,688,327
-929,737
| -7% | -$84.1M | 0.24% | 91 |
|
|
2015
Q4 | $1.59B | Buy |
12,618,064
+1,133,873
| +10% | +$137M | 0.4% | 43 |
|
|
2015
Q3 | $1.2B | Buy |
11,484,191
+905,507
| +9% | +$116M | 0.32% | 60 |
|
|
2015
Q2 | $1.31B | Buy |
10,578,684
+394,066
| +4% | +$49.7M | 0.31% | 56 |
|
|
2015
Q1 | $1.2B | Sell |
10,184,618
-241,616
| -2% | -$28.9M | 0.27% | 69 |
|
|
2014
Q4 | $1.24B | Sell |
10,426,234
-165,171
| -2% | -$18.6M | 0.28% | 71 |
|
|
2014
Q3 | $1.19B | Buy |
10,591,405
+955,407
| +10% | +$91M | 0.28% | 67 |
|
|
2014
Q2 | $912M | Buy |
9,635,998
+2,029,309
| +27% | +$142M | 0.23% | 84 |
|
|
2014
Q1 | $538M | Sell |
7,606,689
-1,573,569
| -17% | -$125M | 0.15% | 162 |
|
|
2013
Q4 | $682M | Buy |
9,180,258
+1,554,124
| +20% | +$108M | 0.19% | 112 |
|
|
2013
Q3 | $578M | Buy |
7,626,134
+748,645
| +11% | +$59.6M | 0.17% | 135 |
|
|
2013
Q2 | $551M | Buy |
+6,877,489
| New | +$506M | 0.18% | 128 |
|
Other funds holding VRTX
JP Morgan Chase's VRTX Position: Q2 2026 in Review
JP Morgan Chase reduced its Vertex Pharmaceuticals (VRTX) stake by 7.3% in Q2 2026, selling an estimated $228M and leaving 6,517,600 shares worth $3.26B. The position accounts for 0.18% of the portfolio, ranked #123.
JP Morgan Chase first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.76B in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- JP Morgan Chase held 6,517,600 shares of Vertex Pharmaceuticals worth $3.26B as of Q2 2026.
- JP Morgan Chase sold 515,556 Vertex Pharmaceuticals shares in Q2 2026, an estimated $228M.
- Vertex Pharmaceuticals made up 0.18% of JP Morgan Chase's portfolio in Q2 2026, its #123 holding.
- JP Morgan Chase first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- JP Morgan Chase's Vertex Pharmaceuticals position peaked at $3.76B in Q1 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.